The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

The aim of this study is to test whether lymphatic surgery provides better QoL (assessed with the Lymph-ICF-UL, (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema)) 15 months after randomization (and therefore about one year after surgery) compared to conservative treatment only for patients with chronic lymphedema (LE)

Trial Details

NCT ID
NCT05890677
Phase
NA
Sponsor
University Hospital, Basel, Switzerland
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Surgical Intervention
  • Conservative Complex Physical Decongestion Therapy
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Rochester, New York, United States|43.15478,-77.61556
  • Sankt Pölten, Lower Austria, Austria|48.20762,15.63725

Key Eligibility Criteria

  • Written informed consent.
  • Patients ≥ 18 years of age.
  • Former diagnosis of breast cancer.
  • Clinical diagnosis of chronic Breast Cancer-Related Lymphedema (BCRL) (persisting for more than 3 months) classified as ≥ Stage 1, according to ISL.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →